Evaluation of Enhanced Peritoneum Permeability in Methylglyoxal-treated Rats as a Diagnostic Method for Peritoneal Damage

[1]  阿部 陽子,et al.  TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model , 2008 .

[2]  H. Sasaki,et al.  Regional Delivery of Model Compounds and 5-Fluorouracil to the Liver by Their Application to the Liver Surface in Rats: Its Implication for Clinical Use , 2005, Pharmaceutical Research.

[3]  H. Sasaki,et al.  Absorption characteristics of model compounds from the small intestinal serosal surface and a comparison with other organ surfaces , 2005, The Journal of pharmacy and pharmacology.

[4]  M. Lam,et al.  Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  H. Sasaki,et al.  Delivery advantage to the unilateral kidney by direct drug application to the kidney surface in rats and pharmacokinetic verification based on a physiological model , 2005, Journal of drug targeting.

[6]  H. Sasaki,et al.  Absorption characteristics of compounds with different molecular weights after application to the unilateral kidney surface in rats. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  T. Nishino,et al.  TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. , 2004, Kidney international.

[8]  Y. Kawaguchi,et al.  Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  M. Pérez-Fontán,et al.  Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  H. Sasaki,et al.  Absorption of phenolsulfonphthalein as a model across the mesenteric surface in rats to determine the drug absorption route after intraperitoneal administration , 2004, The Journal of pharmacy and pharmacology.

[11]  K. Fushimi,et al.  An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2001) 1 , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[12]  T. Hosoya,et al.  Hyper-Vascular Change and Formation of Advanced Glycation Endproducts in the Peritoneum Caused by Methylglyoxal and the Effect of an Anti-Oxidant, Sodium Sulfite , 2003, American Journal of Nephrology.

[13]  T. Nishino,et al.  Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. , 2003, Kidney international.

[14]  A. Jörres.  Glucose Degradation Products in Peritoneal Dialysis: From Bench to Bedside , 2003, Kidney and Blood Pressure Research.

[15]  T. Niwa,et al.  Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  S. Teraoka,et al.  The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. , 2002, Pharmacological research.

[17]  M. Soma,et al.  Sclerosing Encapsulating Peritonitis: Regional Changes of Peritoneum , 2002, Nephron.

[18]  P. Stenvinkel,et al.  Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  S. Kawakami,et al.  Absorption characteristics of model compounds with different molecular weights from the serosal caecal surface in rats , 2002, The Journal of pharmacy and pharmacology.

[20]  H. Sasaki,et al.  Effect of instillation method on the absorption of phenolsulphonphthalein as a model drug from the liver and small intestinal serosal surface in rats , 2001, The Journal of pharmacy and pharmacology.

[21]  B. Grabensee,et al.  Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. , 2001, Kidney international. Supplement.

[22]  H. Ha,et al.  High glucose–induced PKC activation mediates TGF-β1 and fibronectin synthesis by peritoneal mesothelial cells , 2001 .

[23]  S. Kawakami,et al.  Effect of viscous additives on drug absorption from the liver surface in rats using phenol red as a model. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  A. Bręborowicz,et al.  Effect of glucose degradation products on human peritoneal mesothelial cell function. , 2000, Journal of the American Society of Nephrology : JASN.

[25]  T. Miyata,et al.  Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis , 1999, FEBS letters.

[26]  H. Sasaki,et al.  Absorption Characteristics of Model Drugs from the Gastric Serosal Surface in Rats , 1999 .

[27]  H. Sasaki,et al.  Absorption of Drugs Applied to the Gastric Serosal Surface in Rats , 1999 .

[28]  H. Sasaki,et al.  Continuous microinstillation of phenol red on liver surface for liver site-selective delivery. , 1999, Biological & pharmaceutical bulletin.

[29]  L. Gotloib,et al.  High Glucose Induces a Hypertrophic, Senescent Mesothelial Cell Phenotype after Long in vivo Exposure , 1999, Nephron.

[30]  K. Nitta,et al.  Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  J. Waniewski,et al.  Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  H. Sasaki,et al.  Effect of Application Volume and Area on the Absorption of Phenol Red, as a Model Drug, from the Liver Surface in Rats , 1997, The Journal of pharmacy and pharmacology.

[33]  H. Sasaki,et al.  Absorption of Phenol Red and Bromphenol Blue as Model Drugs from the Peritoneal Cavity around the Liver Surface in Rats , 1995, The Journal of pharmacy and pharmacology.

[34]  H. Sasaki,et al.  Effect of albumin on the absorption of phenol red, bromphenol blue and bromosulphonphthalein as model drugs from the liver surface membrane in rats. , 1995, Biological & pharmaceutical bulletin.

[35]  H. Sasaki,et al.  Mechanism for Drug Absorption from Rat‐liver Surface Membrane: Effect of Dose and Transport Inhibitors on the Pharmacokinetics of Phenol Red , 1995, The Journal of pharmacy and pharmacology.

[36]  H. Sasaki,et al.  Absorption of Organic Anions as Model Drugs Following Application to Rat Liver Surface In‐vivo , 1994, The Journal of pharmacy and pharmacology.

[37]  J. Rottembourg.  Residual renal function and recovery of renal function in patients treated by CAPD. , 1993, Kidney international. Supplement.

[38]  Kiyoshi Yamaoka,et al.  Statistical moments in pharmacokinetics , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[39]  L. Hart,et al.  The Chemical Forms in Which Phenol Red is Secreted into the Bile Of Rats , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[40]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[41]  W. van Biesen,et al.  The impact of residual renal function on the adequacy of peritoneal dialysis. , 1997, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[42]  K. Nitta,et al.  Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. , 1996, Nephron.

[43]  G. Sozzi,et al.  Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. , 1996, Cytogenetics and cell genetics.

[44]  F. Mignon,et al.  Nephrology Dialysis Transplantation the Influence of Automated Peritoneal Dialysis on the Decrease in Residual Renal Function , 2022 .